Novozymes A/S

CPSE:NSIS B Stock Report

Market Cap: DKK 182.1b

Novozymes Valuation

Is NSIS B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NSIS B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DKK 574.66
Fair Value
31.9% undervalued intrinsic discount
17
Number of Analysts

Below Fair Value: NSIS B (DKK391.1) is trading below our estimate of fair value (DKK574.66)

Significantly Below Fair Value: NSIS B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NSIS B?

Key metric: As NSIS B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NSIS B. This is calculated by dividing NSIS B's market cap by their current earnings.
What is NSIS B's PE Ratio?
PE Ratio43.2x
Earnings€564.70m
Market Cap€24.39b

Price to Earnings Ratio vs Peers

How does NSIS B's PE Ratio compare to its peers?

The above table shows the PE ratio for NSIS B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.9x
DSFIR DSM-Firmenich
26x14.41%€18.7b
600309 Wanhua Chemical Group
19x20.98%CN¥208.4b
ASIANPAINT Asian Paints
62.9x13.14%₹2.3t
SIKA Sika
23.7x8.59%CHF 29.0b
NSIS B Novozymes
43.2x17.09%DKK 182.1b

Price-To-Earnings vs Peers: NSIS B is expensive based on its Price-To-Earnings Ratio (43.2x) compared to the peer average (32.9x).

Price to Earnings Ratio vs Industry

How does NSIS B's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NSIS B 43.2xIndustry Avg. 17.9xNo. of Companies11PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NSIS B is expensive based on its Price-To-Earnings Ratio (43.2x) compared to the European Chemicals industry average (17.9x).

Price to Earnings Ratio vs Fair Ratio

What is NSIS B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NSIS B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.2x
Fair PE Ratio29.8x

Price-To-Earnings vs Fair Ratio: NSIS B is expensive based on its Price-To-Earnings Ratio (43.2x) compared to the estimated Fair Price-To-Earnings Ratio (29.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NSIS B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 391.10
DKK 466.31
+19.23%
12.13%DKK 569.00DKK 376.00n/a17
Sep ’26DKK 403.40
DKK 469.48
+16.38%
11.87%DKK 569.00DKK 380.00n/a17
Aug ’26DKK 420.80
DKK 500.12
+18.85%
12.86%DKK 577.00DKK 390.00n/a17
Jul ’26DKK 455.60
DKK 503.88
+10.60%
12.31%DKK 577.00DKK 389.00n/a17
Jun ’26DKK 461.80
DKK 496.22
+7.45%
11.52%DKK 577.00DKK 389.00n/a17
May ’26DKK 430.20
DKK 484.94
+12.72%
11.73%DKK 576.00DKK 388.00n/a16
Apr ’26DKK 403.50
DKK 491.31
+21.76%
11.81%DKK 598.00DKK 388.00n/a16
Mar ’26DKK 434.40
DKK 489.12
+12.60%
11.26%DKK 598.00DKK 388.00n/a16
Feb ’26DKK 413.20
DKK 486.24
+17.68%
11.77%DKK 598.00DKK 372.00n/a16
Jan ’26DKK 407.70
DKK 485.12
+18.99%
11.97%DKK 598.00DKK 364.00n/a16
Dec ’25DKK 413.70
DKK 484.05
+17.01%
11.69%DKK 586.00DKK 364.00n/a16
Nov ’25DKK 432.10
DKK 488.00
+12.94%
11.08%DKK 560.00DKK 360.00n/a15
Oct ’25DKK 473.40
DKK 487.50
+2.98%
10.97%DKK 560.00DKK 360.00DKK 395.3016
Sep ’25DKK 468.00
DKK 464.99
-0.64%
11.12%DKK 540.00DKK 360.00DKK 403.4016
Aug ’25DKK 435.80
DKK 458.43
+5.19%
10.63%DKK 540.00DKK 360.00DKK 420.8016
Jul ’25DKK 422.40
DKK 449.81
+6.49%
10.68%DKK 540.00DKK 350.00DKK 455.6016
Jun ’25DKK 408.60
DKK 437.35
+7.04%
9.11%DKK 500.00DKK 350.00DKK 461.8014
May ’25DKK 383.60
DKK 430.86
+12.32%
9.16%DKK 500.00DKK 350.00DKK 430.2014
Apr ’25DKK 405.20
DKK 419.78
+3.60%
9.62%DKK 500.00DKK 340.00DKK 403.5014
Mar ’25DKK 392.20
DKK 408.29
+4.10%
8.55%DKK 460.00DKK 326.00DKK 434.4014
Feb ’25DKK 371.60
DKK 397.38
+6.94%
8.21%DKK 450.00DKK 326.00DKK 413.2013
Jan ’25DKK 371.10
DKK 386.62
+4.18%
8.05%DKK 430.00DKK 326.00DKK 407.7013
Dec ’24DKK 356.10
DKK 376.54
+5.74%
9.00%DKK 430.00DKK 326.00DKK 413.7013
Nov ’24DKK 316.40
DKK 361.77
+14.34%
11.87%DKK 430.00DKK 275.00DKK 432.1013
Oct ’24DKK 284.70
DKK 374.00
+31.37%
12.55%DKK 460.00DKK 275.00DKK 473.4013
DKK 466.31
Fair Value
16.1% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/06 02:52
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novozymes A/S is covered by 41 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael Vitfell-RasmussenABG Sundal Collier
Carla BänzigerBank Vontobel AG
Sebastian SatzBarclays